...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: New PP on Aug 13

On Sedar.  4 different investors from Caymans, Liechtenstein, BC and PQ subscribed for a total of 103,000 units (share + 1/2 warrant) at $2.65CDN/unit.

4
Aug 20, 2019 03:25AM
7
Aug 20, 2019 10:22AM
2
Aug 21, 2019 07:40AM
Share
New Message
Please login to post a reply